The global myocardial infarction market is anticipated to grow at a CAGR of around 6.6% during the forecast period (2021-2027). Factors contributing to the growth of the myocardial infarction market include rising incidence rate of CVDs (cardiovascular diseases) and intake of high-level sugary food, which significantly boost the prevalence of CADs (coronary artery diseases). According to the American Heart Association estimates, CVD is the leading global cause of death and accounted for approximately 18.6 million deaths in 2019. Further, according to WHO, CVDs are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. 4 out of 5 CVD deaths are due to heart attacks and strokes, and one-third of these deaths occur prematurely in people under 70 years of age. Due to the rising prevalence of cardiovascular disease which is the leading cause of mortality, the demand for early detection technologies and diagnostic methods such as ECG, CT-Scan, Echocardiography is increasing, which further driving the market growth.
(Get 15% Discount on Buying this Report)
Get Report Sample Copy @ https://www.omrglobal.com/request-sample/myocardial-infarction-market
Apart from this, the major market players are also taking initiatives by adopting various strategies such as mergers and acquisitions to expand their product offering and launching new technologies to fulfil the demands of the market and healthcare sector. For instance, in October 2020, Abbott had launched next-generation heart rhythm management devices, the Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy Defibrillator (CRT-D) in India. The devices are used for people with abnormal heart rhythms and heart failure. Both the devices offer patient engagement and remote monitoring through smartphone connectivity and connected applications. Moreover, in Jan 2021, Boston Scientific has announced the acquisition of Preventice Solutions, Inc, which offers a full portfolio of mobile cardiac health solutions and services. The acquisition was under a definitive agreement of $925 million. The acquisition will aid Boston Scientific to expand its position in the high-growth ambulatory electrocardiography space, and further help to enter into the implantable cardiac monitor market to expand its cardiac diagnostics and services. Thus, such type of strategies adopted by key players is expected to enhance the market prospects for further growth and developments.
A Full Report of Global Myocardial Infarction Market is Available at https://www.omrglobal.com/industry-reports/myocardial-infarction-market
Key questions addressed by the report:
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Myocardial Infarction Market Report Segment
By Type
- Non-St-Elevation Myocardial Infarction (NSTEMI)
- St-Elevation Myocardial Infarction (STEMI) Heart Attack
- Silent Heart Attack
By Device
- Left Ventricular Assist Device
- Pacemaker
- Catheters
- Implantable Cardioverter Defibrillator
- Others
By Diagnosis
- Electrocardiography (ECG)
- Chest X-Ray
- Computed Tomography (Ct Scan)
- Echocardiography
- Others
By Treatment
- Medication
o Analgesics
o Thrombolytic
o Anti-Platelet Agents
o Glycoprotein LIB/LIB Inhibitors
o Others (Beta-Adrenergic Blockers and Angiotensin-Receptor Blockers)
- Surgery
o Angioplasty
o CABG
o Heart Transplant
By End-Users
- Hospitals and Clinics
- Ambulatory Surgical Centers
- Research Institutes
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
